Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Atherosclerosis Reports
Erschienen in: Current Atherosclerosis Reports 1/2020

01.01.2020 | Evidence-Based Medicine, Clinical Trials and Their Interpretations (L. Roever, Section Editor)

Non-alcoholic Fatty Liver Disease and Its Links with Inflammation and Atherosclerosis

verfasst von: Luan Rodrigues Abdallah, Ricardo Cardoso de Matos, Yves Pacheco Dias March e Souza, Débora Vieira-Soares, Gabriela Muller-Machado, Priscila Pollo-Flores

Erschienen in: Current Atherosclerosis Reports | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We summarize best data of the association between non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD).

Recent Findings

NAFLD has been linked with insulin resistance, obesity, and metabolic syndrome, conditions known to be associated with CVD and subclinical atherosclerosis. The rising evidence of the association between NAFLD and subclinical CVD may suggest that NAFLD is not only a marker but also may be actively involved in pathogenesis of CVD.

Summary

It is an overview of previous studies assessing relationships between NAFLD and markers of cardiovascular disease, as the presence of coronary artery calcification, increased arterial stiffness, and elevated carotid media thickness, in order to better understand the interplay between these conditions.
Literatur
1.
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–128.CrossRefPubMed
2.
Khot U, Khotm M, Bajzer C, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898–904.CrossRefPubMed
3.
Lazo M. Clark Jm. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28(4):339–50.CrossRefPubMed
4.
D’Adamo E. Cali Am, Weiss R, et al. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care. 2010;33(8):1817–22.CrossRefPubMedPubMedCentral
5.
Kotronen A, YkiJarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(1):27–38.CrossRefPubMed
6.
Kotronen A, Velagapudi VR, Yetukuri L, et al. Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia. 2009;52(4):684–90.CrossRefPubMed
7.
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50.CrossRefPubMed
8.
Pacifico L. Nobiliv, Anania C, et al. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol. 2011;17(26):3082–91.PubMedPubMedCentral
9.
Schwimmer JB, Pardee PE, Lavine JE, et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118(3):277–83.CrossRefPubMedPubMedCentral
10.
Sorrentino P, Terracciano L, D’Angelo S, et al. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMAIR, and hypertension. Am J Gastroenterol. 2010;105(2):336–44.CrossRefPubMed
11.
Youssoni ZM, Blissett D, Blissett T, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577–86.CrossRef
12.
Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–52.CrossRefPubMed
13.
•• Targher G, Byrne C, Lonardo A, et al. Nonalcoholic fatty liver disease and risk of incident cardiovascular disease: a metaanalysis. J Hepatol. 2016;65(3):589–600 Excelent metaanalysis that quantify themagnitude of the association between NAFLD (and its severity) and risk of CVD events. CrossRefPubMed
14.
15.
Bugianesi E, Gastaldelli A. Hepatic and cardiac steatosis: Are they coupled? Heart Fail Clin. 2012;8(4):663–70.CrossRefPubMed
16.
Gaggini M, Morelli M, Buzzigoli E, et al. Nonalcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–60.CrossRefPubMedPubMedCentral
17.
Hamagushi M, Kojima T, Takeda N. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13(10):1579–84.CrossRef
18.
Choi DH, Lee SJ, Kang CD, et al. Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. World J Gastroenterol. 2013;19(38):6453–7.CrossRefPubMedPubMedCentral
19.
Perera N, Indrakumar J, Abeysinghe WV, et al. Nonalcoholic fatty liver disease increases the mortality from acute coronary syndrome: an observational study from Sri Lanka. BMC Cardiovasc Disord. 2016;16:37.CrossRefPubMedPubMedCentral
20.
Gastaldelli A, Kozakova M, Højlund K, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009;49(5):1537–44.CrossRefPubMed
21.
Kozakova M, Palombo C, Eng MP, et al. Fatty liver index, gammaglutamyltransferase, and early carotid plaques. Hepatology. 2012;55(5):1406–15.CrossRefPubMed
22.
ZelberSagi S, Salomone F, Yeshua H, et al. Nonhighdensity lipoprotein cholesterol independently predicts new onset of nonalcoholic fatty liver disease. Liver Int. 2014;34(6):e128–35.CrossRef
23.
Wu S, Wu F, Ding Y, et al. Association of nonalcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and metaanalysis. Sci Rep. 2016;6:33386.CrossRefPubMedPubMedCentral
24.
Bonci E, Chiesa C, Versacci P, et al. Association of nonalcoholic fatty liver disease with subclinical cardiovascular changes: a systematic review and metaanalysis. Biomed Res Int. 2015;213737:2015.
25.
Ridker PM, Hennekens CH, Buring JE, et al. Creactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–43.CrossRefPubMed
26.
Assy N, Bekirov I, Mejritsky Y, et al. Association between thrombotic risk factors and extent of fibrosis in patients with nonalcoholic fatty liver diseases. World J Gastroenterol. 2005;11(37):5834–9.CrossRefPubMedPubMedCentral
27.
Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in nonalcoholic steatohepatitis (NASH). Int J Mol Sci. 2013;14(10):20704–28.CrossRefPubMedPubMedCentral
28.
Targher G, Bertolini L, Scala L, et al. Associations between serum 25hydroxyvitamin D3 concentrations and liver histology in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007;17(7):517–24.CrossRefPubMed
29.
Li XL, Sui JQ, Lu LL, et al. Gene polymorphisms associated with nonalcoholic fatty liver disease and coronary artery disease: a concise review. Lipids Health Dis. 2016;15:53.CrossRefPubMedPubMedCentral
30.
Lee YJ, Shim JY, Moon BS, et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57(1):196–203.CrossRefPubMed
31.
Targher G, Bertolini L, Padovani R, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29(6):1325–30.CrossRefPubMed
32.
Madan SA, John F, Pyrsopoulos N, et al. Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: a metaanalysis. Eur J Gastroenterol Hepatol. 2015;27(11):1237–48.CrossRefPubMed
33.
Pacifico L, Anania C, Martino F, et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology. 2010;52(5):1643–165.CrossRefPubMed
34.
Weghuber D, Rodenm M, Franz C, et al. Vascular function in obese children with nonalcoholic fatty liver disease. Int J Pediatr Obes. 2011;6(2):120–7.CrossRefPubMed
35.
Torun E, Aydin S, Gökçe S, et al. Carotid intima media thickness and flowmediated dilation in obese children with nonalcoholic fatty liver disease. Turk J Gastroenterol. 2014;25(Suppl. 1):92–8.PubMed
36.
37.
Zieman S, Melenovsky V, Kass D. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(5):932–43.CrossRefPubMed
38.
Johnson C, Baugh R, Wilson C, et al. Age related changes in the tunica media of the vertebral artery: implications for the assessment of vessels injured by trauma. J Clin Pathol. 2001;54(2):139–45.CrossRefPubMedPubMedCentral
39.
VilellaNogueira C, Leite N, Cardoso C, et al. NAFLD and increased aortic stiffness: parallel or common physiopathological mechanisms? Int J Mol Sci. 2016;17(4):460.CrossRef
40.
Harisson S. Nonalcoholic fatty liver disease and fibrosis progression:the good, the bad, and the unknown. Clin Gastroenterol Hepatol. 2015;13(4):655–7.CrossRef
41.
Shiotani A, Motoyama M, Matsuda T, et al. Brachialankle pulse wave velocity in Japanese university students. Intern Med. 2005;44(7):696–701.CrossRefPubMed
42.
Vlachopoulos C, Manesis E, Baou K, et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: a pilot study. Am J Hypertens. 2010;23:1183–9.CrossRefPubMed
43.
Kim B, Kim N, Kim BS, et al. The association between nonalcoholic fatty liver disease,metabolic syndrome and arterial stiffness in nondiabetic, nonhypertensive individuals. Cardiology. 2012;123:54–61.CrossRefPubMed
44.
Huang Y, Bi Y, Xu M, et al. Nonalcoholic fatty liver disease is associated with atherosclerosis in middleaged and elderly Chinese. Arterioscler Thromb Vasc Biol. 2012;32:2321–6.CrossRefPubMed
45.
Huang C, Beilin J, Ayonrinde O, et al. Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents. Hepatology. 2013;58(4):1306–14.CrossRefPubMed
46.
47.
Sunbulm A. Durmus E, et al. Arterial stiffness in patients with nonalcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis. 2014;237(2):490–3.CrossRef
48.
• Haradap BI, Drager F. Nonalcoholic fatty liver disease presence and severity is associated with aortic stiffness beyond abdominal obesity: the ELSABrasil. Atherosclerosis. 2019;284:59–65 This crosssectional study demonstrates the association of NAFLD with aortic stiffness in a racially/ethnically diverse population free of CVD. CrossRef
49.
50.
Lin Z. G, Zhang J, et al. Nonalcoholic fatty liver disease is associated with progression of arterial stiffness. Nutr Metab Cardiovasc Dis. 2015;25(2):218–23.CrossRef
51.
Silverman M, Blaha M, Krumholz H, et al. Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the multiethnic study of atherosclerosis. Eur Heart J. 2014;35(33):2232–41.CrossRefPubMed
52.
Al Rifai M, Silverman M, Nasir K. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the multiethnic study of atherosclerosis (MESA). Atherosclerosis. 2015;239(2):629–33.CrossRefPubMedPubMedCentral
53.
54.
Kim D, Choi S, Park E, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology. 2012;56(2):605–13.CrossRefPubMed
55.
Gummesson A, Strömberg U, Schmidt C. Nonalcoholicfatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: a crosssectional, populationbased study in middleaged subjects. PLoS One. 2018;13(8):e0202666. https://​doi.​org/​10.​1371/​journal.​pone.​0202666eCollection 2018.
56.
• Cho Y, Kang Y, Yoo J. The impact of nonalcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification. Sci Rep. 2018;8:12004 First study to demonstratethat NAFLD is an independent contributor to CAC progression, irrespective of the presence of metabolic syndrome. CrossRefPubMedPubMedCentral
57.
• Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis. 2019;282:110–20 Critical review of the association of NAFLD and CVD. CrossRefPubMed
Metadaten
Titel
Non-alcoholic Fatty Liver Disease and Its Links with Inflammation and Atherosclerosis
verfasst von
Luan Rodrigues Abdallah
Ricardo Cardoso de Matos
Yves Pacheco Dias March e Souza
Débora Vieira-Soares
Gabriela Muller-Machado
Priscila Pollo-Flores
Publikationsdatum
01.01.2020
Verlag
Springer US
Erschienen in
Current Atherosclerosis Reports / Ausgabe 1/2020
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-020-0820-8

Weitere Artikel der Ausgabe 1/2020

Current Atherosclerosis Reports 1/2020 Zur Ausgabe

Reviews and New Research Implications (S. Virani, Section Editor)

Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions

Correction

Correction to: Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents

Nonstatin Drugs (R. Carmena, Section Editor)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases

Evidence-Based Medicine, Clinical Trials and Their Interpretations (L. Roever, Section Editor)

Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents

Correction

Correction to: Carotid Atherosclerosis in Patients with Atrial Fibrillation

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

RAS-Blocker bei Hyperkaliämie möglichst nicht sofort absetzen

14.05.2024 Hyperkaliämie Nachrichten

Bei ausgeprägter Nierenfunktionsstörung steigen unter der Einnahme von Renin-Angiotensin-System(RAS)-Hemmstoffen nicht selten die Serumkaliumspiegel. Was in diesem Fall zu tun ist, erklärte Prof. Jürgen Floege beim diesjährigen Allgemeinmedizin-Update-Seminar.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise